首页> 美国卫生研究院文献>The Turkish Journal of Gastroenterology >P-012. Efficacy and safety of Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin in chronic hepatitis C patients with chronic renal failure

【2h】

P-012. Efficacy and safety of Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin in chronic hepatitis C patients with chronic renal failure

机译：P-012。 Paritaprevir / Ritonavir + Ombitasvir±Dasabuvir±Ribavirin在慢性丙型肝炎慢性肾衰竭患者中的疗效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Chronic hepatitis C (CHC) is common in patients with chronic kidney disease who are on hemodialysis. Because sofosbuvir is eliminated mainly by kidney, sofosbuvir-based regimens are not recommended in patients with estimated glomerular filtration rate (eGFR) < 30 ml/dak/1,73 m . In the present study, we aimed to evaluate the efficacy and safety of paritaprevir/ritonavir+ombitasvir+dasabuvir (PrOD) or paritaprevir/ritonavir+ombitasvir (PrO) in CHC patients with chronic renal failure (CRF) who were on hemodialysis.

机译：慢性丙型肝炎（CHC）在接受血液透析的慢性肾脏疾病患者中很常见。由于索非布韦主要被肾脏清除，因此对于估计肾小球滤过率（eGFR）<30 ml / dak / 1,73 m的患者，不建议使用基于索非布韦的方案。在本研究中，我们旨在评估paritaprevir / ritonavir + ombitasvir + dasabuvir（PrOD）或paritaprevir / ritonavir + ombitasvir（PrO）在接受血液透析的CHC慢性肾衰竭（CRF）患者中的疗效和安全性。

著录项

期刊名称 The Turkish Journal of Gastroenterology
作者
Fatih Güzelbulut; Ekrem Aslan; Ayça Gökçen Değirmenci Saltürk; Özgür Bahadır; Halil Şahin; Mevlüt Kiyak; Emine Kanatsız; Mustafa Keçeci;
展开▼
作者单位

展开▼
年(卷),期 2019(30),supp1
年度 2019
页码 -1
总页数 2
原文格式 PDF
正文语种
中图分类肠道病毒与肝炎病毒;肝及胆疾病;肠疾病;
关键词
HCV; CRF; paritaprevir/ritonavir+ombitasvir±dasabuvir±ribavirin; SVR12;

机译：HCV;CRF;帕瑞他韦/利托那韦+ ombitasvir±达沙布韦±利巴韦林;SVR12;

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Ombitasvir plus Paritaprevir,Ritonavir and Ribavirin in Non-cirrhotic Treatment-naive and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection [J] . Manar Ahmed, Azza E.Mansey, Engy A.Wahsh, 当代医学科学(英文) . 2021,第003期
2. RUBY-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in Adults with Genotype 1 Chronic Hepatitis C Virus (HCV) Infection with Severe Renal Impairment or End-Stage Renal Disease [J] . Vierling John M., Lawitz Eric, Reddy K. Rajender, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Ruby-I：omombitasvir / paritaprevir / ritonavir和dasbuvir的安全性和有效性，或没有利基霉素在成人中，具有基因型1慢性丙型肝炎病毒（HCV）感染严重肾损伤或末期肾病
3. Real-life data on the efficacy and safety of ombitasvir/paritaprevir/ritonavir + dasabuvir +ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia [J] . Simonovi?-Babi? Jasmina, Bojovi? Ksenija, Fabri Milotka, Vojnosanitetski Pregled . 2019,第5期

机译：ombitasvir / paritaprevir / ritonavir + dasabuvir + ribavirin在基因型1型慢性丙型肝炎病毒感染塞尔维亚患者中的疗效和安全性的现实数据
4. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis [J] . Poordad Fred, Sedghi Shahriar, Pockros Paul J., Journal of viral hepatitis. . 2019,第8期

机译：慢性丙基肝炎病毒基因型1A感染患者慢性丙型肝炎病毒基因型1A感染患者的疗效和安全性的疗效和安全性和Dasbuvir
5. Studies of Therapy with Thymosin α 1 in Combination with Pegylated Interferon α2a and Ribavirin in Nonresponder Patients with Chronic Hepatitis C [C] . ROBERTO CAMERINI, ALESSIA CIANCIO, ALFONSO DE ROSA, International Symposiumn on Thymosins in Health and Disease; 20070321-24; Washington,DC(US) . 2007

机译：胸腺素α1联合聚乙二醇化干扰素α2a和利巴韦林治疗慢性丙型肝炎无反应者的研究
6. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
7. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials [O] . Jason Grebely, Massimo Puoti, Heiner Wedemeyer, 2018

机译：Ombitasvir / Paritaprevir / Ritonavir和Dasabuvir联合或不联合利巴韦林在接受阿片类药物替代治疗的慢性丙型肝炎病毒基因型1感染患者中的疗效和安全性：对12项临床试验的事后分析
8. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis [O] . Fred Poordad, Shahriar Sedghi, Paul J. Pockros, 2019

机译：慢性丙基肝炎病毒基因型1A感染患者慢性丙基肝炎病毒基因型1A感染的疗效和Dasabuvir和Dasbuvir的疗效和安全性

P-012. Efficacy and safety of Paritaprevir/Ritonavir + Ombitasvir ± Dasabuvir ± Ribavirin in chronic hepatitis C patients with chronic renal failure

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅